[{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Indian Council of Medical Research \/ Bharat Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Indian Council of Medical Research \/ Bharat Biotech"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"LifeCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"LifeCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LifeCell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LifeCell \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : AKS-452

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : AKS-452 is a CoV-2 protein subunit vaccine based on the Ambifect™ Fc-fusion protein platform. It induces a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein.

                          Product Name : AKS-452

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 24, 2022

                          Lead Product(s) : AKS-452

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Strides Pharma Science

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : DengiAll, a single-dose live-attenuated tetravalent vaccine induced robust, balanced neutralizing antibody responses against all four Dengue virus serotypes. After single-dose, more than 80% of participants showed Tri-valent response and ~95% showed mult...

                          Product Name : DengiAll

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 30, 2021

                          Lead Product(s) : Tetravalent Chimeric Dengue Vaccine Recombinant

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Derived from Mesenchymal stem cells obtained from donated umbilical cord tissue, Mesocel is set to treat patients suffering from life-threatening Covid-19 pneumonia and acute respiratory distress.

                          Product Name : Mesocel

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          September 15, 2021

                          Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.

                          Product Name : HGCO19

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          August 31, 2021

                          Lead Product(s) : HGCO19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : HDT Biotech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : HCCOG19 is an indigenously developed vaccine on a mRNA platform. Gennova has initiated the enrolment of volunteers for Phase 1/2 clinical trials for its mRNA vaccine candidate HGCO19, the Department of Biotechnology.

                          Product Name : HGCO19

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          April 13, 2021

                          Lead Product(s) : HGCO19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : CEPI will initially contribute up to $5m toward the cost of scaling up the process for manufacturing the COVAX, and will explore providing additional funding to Bio E with the goal of potentially enabling the production of 100 million doses in 2021.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 29, 2020

                          Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : CEPI

                          Deal Size : $5.0 million

                          Deal Type : Funding

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Zydus Cadila's ZyCoV-D', has been found to be safe and immunogenic in the Phase I/II clinical trials, and the company is seeking regulatory approval to commence Phase-III trials.

                          Product Name : ZyCoV-D

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 24, 2020

                          Lead Product(s) : ZyCoV-D

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Company said in November it had started early-stage and mid-stage human trials of its vaccine candidate, being developed in collaboration with Baylor College of Medicine in Houston and U.S.-based Dynavax Technologies Corp, and expects results by February...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 18, 2020

                          Lead Product(s) : COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Bayer college of medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : International Finance Corporation has invested $30 million, or about Rs 221 crore, in Indian vaccine maker Biological E to help the latter expand its range of low-priced, generic vaccines for routine immunisation of children and new vaccines including fu...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 17, 2020

                          Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : International Finance Corporation

                          Deal Size : $30.0 million

                          Deal Type : Funding

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : BE's Phase I/II clinical trial will evaluate the safety and immunogenicity of the vaccine candidate consisting of the Receptor Binding Domain of the Spike Protein of SARS-CoV-2 at three dose levels adjuvanted with CpG 1018 plus alum, in about 360 healthy...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          November 16, 2020

                          Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Dynavax Technologies

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank